natgillin/translations-raw huggingface dataset:
Eporatio 2,000 IU/0.5 ml: One pre-filled syringe contains 2,000 international units (IU) (16.7 micrograms) epoetin theta in 0.5 ml solution for injection corresponding to 4,000 international units (IU) (33.3 micrograms) per ml. 
Eporatio 2000 IU/0,5 ml: Jedna napunjena štrcaljka sadrži 2000 internacionalnih jedinica (IU) (16,7 mikrograma) epoetina theta u 0,5 ml otopine za injekciju što odgovara 4000 internacionalnih jedinica (IU) (33,3 mikrograma) po ml.
Eporatio 10,000 IU/1 ml solution for injection in pre-filled syringe 1 ml solution in a pre-filled syringe (type I glass) with a tip cap (bromobutyl rubber), a plunger stopper (teflonised chlorobutyl rubber) and an injection needle (stainless steel) or an injection needle (stainless steel) with a safety shield (safety needle) or an injection needle (stainless steel) with a safety device. 
1 ml otopine u napunjenoj štrcaljki (staklo tip I) sa zatvaračem vrha (bromobutil guma), čepom klipa (teflonizirana klorobutil guma) i injekcijskom iglom (nehrđajući čelik) ili injekcijskom iglom (nehrđajući čelik) sa sigurnosnim štitnikom (sigurnosna igla) ili injekcijskom iglom (nehrđajući čelik)
Eporatio 20,000 IU/1 ml solution for injection in pre-filled syringe One pre-filled syringe contains 20,000 international units (IU) (166.7 µg) epoetin theta in 1 ml solution for injection corresponding to 20,000 IU (166.7 µg) epoetin theta per ml. 
Eporatio 20 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki Jedna napunjena štrcaljka sadrži 20 000 internacionalnih jedinica (IU) (166,7 μg) epoetina theta u 0,5 ml otopine za injekciju, što odgovara 20 000 IU (166,7 μg) epoetina theta po ml.
Eporatio 5,000 IU/0.5 ml solution for injection in pre-filled syringe One pre-filled syringe contains 5,000 international units (IU) (41.7 µg) epoetin theta in 0.5 ml solution for injection corresponding to 10,000 IU (83.3 µg) epoetin theta per ml. 
Eporatio 5000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki Jedna napunjena štrcaljka sadrži 5000 internacionalnih jedinica (IU) (41,7 μg) epoetina theta u 0,5 ml otopine za injekciju, što odgovara 10 000 IU (83,3 μg) epoetina theta po ml.
Eporatio 4,000 IU/0.5 ml solution for injection in pre-filled syringe One pre-filled syringe contains 4,000 international units (IU) (33.3 µg) epoetin theta in 0.5 ml solution for injection corresponding to 8,000 IU (66.7 µg) epoetin theta per ml. 
Eporatio 4000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki Jedna napunjena štrcaljka sadrži 4000 internacionalnih jedinica (IU) (33,3 μg) epoetina theta u 0,5 ml otopine za injekciju, što odgovara 8000 IU (66,7 μg) epoetina theta po ml.
Eporatio 1,000 IU/0.5 ml solution for injection in pre-filled syringe 0.5 ml solution in a pre-filled syringe (type I glass) with a tip cap (bromobutyl rubber), a plunger stopper (teflonised chlorobutyl rubber) and an injection needle (stainless steel) or an injection needle (stainless steel) with a safety shield (safety needle) or an injection needle (stainless steel) with a safety device. 
0,5 ml otopine u napunjenoj štrcaljki (staklo tip I) sa zatvaračem vrha (bromobutil guma), čepom klipa (teflonizirana klorobutil guma) i injekcijskom iglom (nehrđajući čelik) ili injekcijskom iglom (nehrđajući čelik) sa sigurnosnim štitnikom (sigurnosna igla) ili injekcijskom iglom (nehrđajući čelik)
Eporatio 20,000 IU/1 ml injection Epoetin theta 
Eporatio 20 000 IU/1 ml injekcija epoetin theta s.c. i.v.
Eporatio 2,000 IU/0.5 ml solution for injection in pre-filled syringe One pre-filled syringe contains 2,000 international units (IU) (16.7 µg) epoetin theta in 0.5 ml solution for injection corresponding to 4,000 IU (33.3 µg) epoetin theta per ml. 
Eporatio 2000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki Jedna napunjena štrcaljka sadrži 2000 internacionalnih jedinica (IU) (16,7 μg) epoetina theta u 0,5 ml otopine za injekciju, što odgovara 4000 IU (33,3 μg) epoetina theta po ml.
Eporatio 3,000 IU/0.5 ml solution for injection in pre-filled syringe One pre-filled syringe contains 3,000 international units (IU) (25 µg) epoetin theta in 0.5 ml solution for injection corresponding to 6,000 IU (50 µg) epoetin theta per ml. 
Eporatio 3000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki Jedna napunjena štrcaljka sadrži 3000 internacionalnih jedinica (IU) (25 μg) epoetina theta u 0,5 ml otopine za injekciju, što odgovara 6000 IU (50 μg) epoetina theta po ml.
Eporatio 20,000 IU/1 ml solution for injection in pre-filled syringe 30 months 
Eporatio 20 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki 30 mjeseci
Eporatio 10,000 IU/1 ml solution for injection in pre-filled syringe 30 months 
Eporatio 10 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki 30 mjeseci
EU/1/09/573/025 EU/1/09/573/026 EU/1/09/573/027 EU/1/09/573/028 EU/1/09/573/040 EU/1/09/573/041 EU/1/09/573/042 
EU/1/09/573/003 EU/1/09/573/004 EU/1/09/573/030
Eporatio 20,000 IU/1 ml solution for injection in pre-filled syringe EU/1/09/573/017 
Eporatio 20 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki EU/1/09/573/017
Eporatio 30,000 IU/1 ml solution for injection in pre-filled syringe 30 months 
Eporatio 30 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki 30 mjeseci
Before you give yourself an Eporatio injection, you must do the following: Hold the syringe and gently remove the cover from the needle without twisting. 
Držite štrcaljku i pažljivo skinite poklopac s igle bez okretanja.
Eporatio 10,000 IU/1 ml injection Epoetin theta 
Eporatio 10 000 IU/1 ml injekcija epoetin theta s.c. i.v.
Eporatio 5,000 IU/0.5 ml injection Epoetin theta 
Eporatio 5000 IU/0,5 ml injekcija epoetin theta s.c. i.v.
Eporatio 30,000 IU/1 ml solution for injection in pre-filled syringe EU/1/09/573/023 
Eporatio 30 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki EU/1/09/573/023
Eporatio 30,000 IU/1 ml injection Epoetin theta 
Eporatio 30 000 IU/1 ml injekcija epoetin theta s.c. i.v.
Eporatio 10,000 IU/1 ml solution for injection in pre-filled syringe EU/1/09/573/011 
Eporatio 10 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki EU/1/09/573/011
Eporatio 20,000 IU/1 ml solution for injection in pre-filled syringe Epoetin theta 
Eporatio 20 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki epoetin theta
Eporatio 30,000 IU/1 ml solution for injection in pre-filled syringe Epoetin theta 
Eporatio 30 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki epoetin theta
Eporatio 4,000 IU/0.5 ml injection Epoetin theta 
Eporatio 4000 IU/0,5 ml injekcija epoetin theta s.c. i.v.
Eporatio 1,000 IU/0.5 ml injection Epoetin theta 
Eporatio 1000 IU/0,5 ml injekcija epoetin theta s.c. i.v.
Eporatio 3,000 IU/0.5 ml injection Epoetin theta 
Eporatio 3000 IU/0,5 ml injekcija epoetin theta s.c. i.v.
Eporatio 1,000 IU/0.5 ml solution for injection in pre-filled syringe 2 years 
Eporatio 1000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki 2 godine
Eporatio 1,000 IU/0.5 ml solution for injection in pre-filled syringe Epoetin theta 
Eporatio 1000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki epoetin theta
Eporatio 20,000 IU/1 ml solution for injection in pre-filled syringe 
Eporatio 20 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki
EU/1/09/573/004 6 pre-filled syringes with safety device EU/1/09/573/030 6 pre-filled syringes with safety needle 
EU/1/09/573/003 6 napunjenih štrcaljki EU/1/09/573/004 6 napunjenih štrcaljki sa sigurnosnom napravom EU/1/09/573/030 6 napunjenih štrcaljki sa sigurnosnom iglom
Eporatio 10,000 IU/1 ml solution for injection in pre-filled syringe Epoetin theta 
Eporatio 10 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki epoetin theta
Eporatio 10,000 IU/1 ml solution for injection in pre-filled syringe 
Eporatio 10 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki
Eporatio 4,000 IU/0.5 ml solution for injection in pre-filled syringe EU/1/09/573/007 
Eporatio 4000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki EU/1/09/573/007
Eporatio 5,000 IU/0.5 ml solution for injection in pre-filled syringe Epoetin theta 
Eporatio 5000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki epoetin theta
Eporatio 5,000 IU/0.5 ml solution for injection in pre-filled syringe EU/1/09/573/009 
Eporatio 5000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki EU/1/09/573/009
Eporatio 30,000 IU/1 ml solution for injection in pre-filled syringe 
Eporatio 30 000 IU/1 ml otopina za injekciju u napunjenoj štrcaljki
Eporatio 2,000 IU/0.5 ml solution for injection in pre-filled syringe Epoetin theta 
Eporatio 2000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki epoetin theta
Eporatio 4,000 IU/0.5 ml solution for injection in pre-filled syringe Epoetin theta 
Eporatio 4000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki epoetin theta
Eporatio 4,000 IU/0.5 ml solution for injection in pre-filled syringe 2 years 
Eporatio 4000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki 2 godine
EU/1/09/573/008 6 pre-filled syringes with safety device EU/1/09/573/032 6 pre-filled syringes with safety needle 
EU/1/09/573/007 6 napunjenih štrcaljki EU/1/09/573/008 6 napunjenih štrcaljki sa sigurnosnom napravom EU/1/09/573/032 6 napunjenih štrcaljki sa sigurnosnom iglom
Eporatio 2,000 IU/0.5 ml injection Epoetin theta 
Eporatio 2000 IU/0,5 ml injekcija epoetin theta s.c. i.v.
EU/1/09/573/006 6 pre-filled syringes with safety device EU/1/09/573/031 6 pre-filled syringes with safety needle 
EU/1/09/573/005 6 napunjenih štrcaljki EU/1/09/573/006 6 napunjenih štrcaljki sa sigurnosnom napravom EU/1/09/573/031 6 napunjenih štrcaljki sa sigurnosnom iglom
Eporatio 2,000 IU/0.5 ml solution for injection in pre-filled syringe 2 years 
Eporatio 2000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki 2 godine
EU/1/09/573/010 6 pre-filled syringes with safety device EU/1/09/573/033 6 pre-filled syringes with safety needle 
EU/1/09/573/009 6 napunjenih štrcaljki EU/1/09/573/010 6 napunjenih štrcaljki sa sigurnosnom napravom EU/1/09/573/033 6 napunjenih štrcaljki sa sigurnosnom iglom
Eporatio 3,000 IU/0.5 ml solution for injection in pre-filled syringe EU/1/09/573/005 
Eporatio 3000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki EU/1/09/573/005
Eporatio 3,000 IU/0.5 ml solution for injection in pre-filled syringe Epoetin theta 
Eporatio 3000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki epoetin theta
Eporatio 1,000 IU/0.5 ml solution for injection in pre-filled syringe EU/1/09/573/001 
Eporatio 1000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki EU/1/09/573/001
Eporatio 3,000 IU/0.5 ml solution for injection in pre-filled syringe 2 years 
Eporatio 3000 IU/0,5 ml otopina za injekciju u napunjenoj štrcaljki 2 godine
EU/1/09/573/002 6 pre-filled syringes with safety device EU/1/09/573/029 6 pre-filled syringes with safety needle 
EU/1/09/573/001 6 napunjenih štrcaljki EU/1/09/573/002 6 napunjenih štrcaljki sa sigurnosnom napravom EU/1/09/573/029 6 napunjenih štrcaljki sa sigurnosnom iglom.
Common in patients with chronic renal failure (may affect up to 1 in 10 people) - Blood clot in the arterio-venous fistula in patients on dialysis. 
Često u bolesnika s kroničnim zatajenjem bubrega (mogu se javiti u do 1 na 10 osoba)
Further information on Exjade can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Više informacija o lijeku Exjade možete naći na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Exjade is taken once a day at around the same time. 
Lijek Exjade uzima se jedanput dnevno u otprilike isto doba svakoga dana.
About half of the patients were under the age of 16 years, and 56 were less than 6 years old. 
Otprilike polovica bolesnika imala je manje od 16 godina, dok je 56 bolesnika imalo manje od 6 godina.
Exjade was not as effective overall as the comparator medicine. 
Lijek Exjade nije u cijelosti bio jednako učinkovit kao usporedni lijek.
Treatment may need to be interrupted or stopped depending on the results of the tests. 
Možda će biti potrebno prekinuti ili obustaviti liječenje, ovisno o rezultatima pretraga.
What is Exjade and what is it used for? 
Što je Exjade i za što se koristi?
It must not be used in combination with other iron chelators. 
Ne smije se primjenjivati u kombinaciji s drugim kelatorima željeza.
Exjade received a marketing authorisation valid throughout the EU on 28 August 2006. 
Lijek Exjade dobio je odobrenje za stavljanje u promet koje je na snazi u EU-u od 28. kolovoza 2006.
What measures are being taken to ensure the safe and effective use of Exjade? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Exjade?
The company that markets Exjade must issue an education pack to healthcare professionals. 
Tvrtka koja proizvodi lijek Exjade mora objaviti edukacijski paket za zdravstvene radnike.
Other information about Exjade 
Ostale informacije o lijeku Exjade
The main measure of effectiveness was the change in iron levels in the liver after 12 months of treatment. 
Glavna mjera učinkovitosti bila je promjena razina željeza u jetri nakon 12 mjeseci liječenja.
In more than half of these patients the iron level was reduced satisfactorily after a year of treatment with Exjade, including patients aged between 2 and 5 years. 
U više od polovice tih bolesnika razina željeza zadovoljavajuće je smanjena nakon jedne godine liječenja lijekom Exjade, uključujući bolesnike u dobi od 2 do 5 godina.
Exjade is a medicine used to treat chronic iron overload (an excess of iron in the body) in: 
Exjade je lijek koji se koristi za liječenje kroničnog preopterećenja željezom (prevelike količine željeza u tijelu) u:
However, in the 381 patients who had particularly high levels of iron at the beginning of the study and who received comparable amounts of Exjade and deferoxamine, the two medicines were as effective as each other. 
Međutim, u 381 bolesnika koji su imali osobito visoke razine željeza na početku ispitivanja i koji su primili usporedive količine lijeka Exjade i deferoksamina, oba ta lijeka bila su jednako djelotvorna.
Side effects reported with Exjade are carefully evaluated and any necessary action taken to protect patients. 
Nuspojave prijavljene za lijek Exjade pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
The body cannot remove iron effectively and excess iron can cause damage. 
Tijelo ne može učinkovito ukloniti željezo te višak željeza može uzrokovati oštećenja.
As for all medicines, data on the use of Exjade are continuously monitored. 
Kao i za sve lijekove, podatci o primjeni lijeka Exjade kontinuirano se prate.
What are the risks associated with Exjade? 
Koji su rizici povezani s lijekom Exjade?
Exjade must not be used in people whose creatinine clearance is less than 60 ml per minute. 
Lijek Exjade ne smiju uzimati ljudi koji imaju klirens kreatinina manji od 60 ml/min.
Effectiveness was determined by the level of iron in the liver before and after one year of treatment. 
Učinkovitost se utvrđivala na osnovi razine željeza u jetri prije i nakon jedne godine liječenja.
For more information about using Exjade, see the package leaflet or contact your doctor or pharmacist. 
Za više informacija o primjeni lijeka Exjade pogledajte uputu o lijeku ili se obratite liječniku ili ljekarniku.
The European Medicines Agency decided that Exjade's benefits are greater than its risks and it can be authorised for use in the EU. 
Europska agencija za lijekove zaključila je da koristi od lijeka Exjade nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u Europskoj uniji.
The dispersible tablets should be taken on an empty stomach (at least 30 minutes before food), and the film-coated tablets and granules can be taken on an empty stomach or with a light meal. 
Tablete za oralnu suspenziju uzimaju se na prazan želudac (najmanje 30 minuta prije obroka), a tablete obložene filmom i granule mogu se uzimati na prazan želudac ili uz lagani obrok.
Why is Exjade authorised in the EU? 
Zašto je lijek Exjade odobren u EU-u?
The granules are sprinkled on soft food such as yogurt or apple sauce that the patient can eat. 
Granule treba posipati na meku hranu, npr. jogurt ili jabučnu kašu, koju bolesnik može pojesti.
The iron level was reduced satisfactorily in 53% of the patients receiving Exjade, compared with 66% of the patients receiving deferoxamine. 
Razina željeza zadovoljavajuće je smanjena u 53 % bolesnika koji su primali lijek Exjade, u usporedbi sa 66 % bolesnika koji su primali deferoksamin.
An overview of Exjade and why it is authorised in the EU 
Pregled informacija o lijeku Exjade i zašto je odobren u EU-u
The active substance in Exjade, deferasirox, is an ‘iron chelator'. 
Djelatna tvar u lijeku Exjade, deferasiroks, jest „kelator željeza”.
In a further main study involving 166 patients from 10 years of age (including 21 patients aged 10 to 18 years) with non-transfusion-dependent thalassaemia syndromes and iron overload, Exjade was more effective than placebo (a dummy treatment). 
U još jednom glavnom ispitivanju u kojem je sudjelovalo 166 bolesnika u dobi od 10 godina i starijih (uključujući 21 bolesnika u dobi od 10 do 18 godina) sa sindromima talasemije neovisnima o transfuziji i preopterećenjem željezom, lijek Exjade pokazao se učinkovitijim od placeba (prividno liječenje).
Other common side effects (in up to 1 patient in 10) include nausea (feeling sick), vomiting, diarrhoea, indigestion, abdominal (belly) pain, constipation, headache, rash, itching, blood tests showing raised transaminases (which may suggest liver damage) and protein in urine. 
Ostale česte nuspojave (u do 1 na 10 bolesnika) jesu mučnina (osjećaj slabosti), povraćanje, proljev, loša probava, abdominalna bol (bol u trbuhu), zatvor, glavobolja, osip, svrbež, povišene transaminaze zabilježene u krvnim pretragama (što može upućivati na oštećenje jetre) i bjelančevine u mokraći.
How is Exjade used? 
Kako se Exjade koristi?
The most common side effect with Exjade (which may affect more than 1 in 10 people) is increased blood creatinine (a marker of kidney problems). 
Najčešća nuspojava lijeka Exjade (koja se može javiti u više od 1 na 10 osoba) jest povišena razina kreatinina u krvi (marker problema s bubrezima).
Another study involved 184 patients who could not be treated with deferoxamine, including patients with beta thalassaemia major and with other types of anaemia. 
U drugom ispitivanju sudjelovalo je 184 bolesnika koji se nisu mogli liječiti deferoksaminom, uključujući bolesnike s beta-talasemijom major i drugim vrstama anemije.
In patients treated with Exjade, liver iron levels decreased on average by 3.8 mg per gram of liver compared with an average increase of 0.4 mg per gram of liver in patients treated with placebo. 
U bolesnika liječenih lijekom Exjade razine željeza u jetri u prosjeku su se smanjile za 3,8 mg po gramu jetre, dok su se u bolesnika liječenih placebom te razine povećale za prosječno 0,4 mg po gramu jetre.
The film-coated tablets are to be swallowed with water while the dispersible tablets are to be mixed with a liquid to make up a suspension that the patient can drink. 
Tablete obložene filmom treba progutati s vodom, a tablete za oralnu suspenziju trebaju se pomiješati s tekućinom radi pripreme suspenzije koju bolesnik može popiti.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Exjade have also been included in the summary of product characteristics and the package leaflet. 
Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Eliquis nalaze se također u sažetku opisa svojstava lijeka i u uputi o lijeku.
Exjade can only be obtained with a prescription and treatment should be started and supervised by a doctor who is experienced in the treatment of chronic iron overload. 
Lijek Exjade izdaje se samo na liječnički recept, a liječenje mora započeti i nadzirati liječnik s iskustvom u liječenju kroničnog preopterećenja željezom.
In chronic iron overload due to blood transfusions, one main study compared Exjade with deferoxamine in 591 patients with beta thalassaemia major. 
U bolesnika s kroničnim preopterećenjem željezom zbog transfuzija krvi lijek Exjade uspoređivan je s deferoksaminom u okviru jednog glavnog ispitivanja na 591 bolesniku s beta-talasemijom major.
The starting dose of Exjade depends on the patient's body weight, on which form of the medicine is being taken, what the medicine is used for, and on the level of iron overload. 
Početna doza lijeka Exjade ovisi o tjelesnoj težini bolesnika, obliku lijeka koji se primjenjuje, razlogu za liječenje i razini preopterećenja željezom.
The company will also perform the following studies: a study on the long-term effects of the filmcoated tablets and dispersible tablets in children aged over 10 years with non-transfusion-dependent thalassaemia; and a study to assess the safety of the film-coated tablets (particularly when they are crushed) in children. 
Osim toga, tvrtka će provesti sljedeća ispitivanja: ispitivanje o dugoročnim koristima tableta obloženih filmom i tableta za oralnu suspenziju na djeci starijoj od 10 godina s talasemijom neovisnom o transfuziji te ispitivanje u okviru kojeg bi se ocjenjivala sigurnost tableta obloženih filmom u djece (osobito kada su zdrobljene).
This pack aims to inform them about the treatment recommendations with Exjade, including choosing the right dose, that the doses are different for dispersible tablets compared to film-coated tablets or granules, and the need to monitor the patient's health, especially kidney function. 
Svrha tog paketa jest obavijestiti zdravstvene radnike o preporukama za liječenja lijekom Exjade, uključujući odabir prave doze, o razlikovanju doze ovisno o tome uzima li bolesnik tablete za oralnu suspenziju ili tablete obložene filmom ili granule te o tome da je potrebno nadzirati bolesnikovo zdravstveno stanje, osobito funkciju rada bubrega.
Cases of metabolic acidosis (when the body produces more acid than it gets rid of) have been reported with Exjade, mostly in patients with kidney impairment. 
Pri uporabi lijeka Exjade zabilježeni su slučajevi metaboličke acidoze (stanja u kojem tijelo proizvodi više kiseline nego što je izlučuje), većinom u bolesnika s oštećenjem bubrega.
How does Exjade work? 
Kako djeluje Exjade?
Kidney and liver tests should be done before starting treatment and at regular intervals during treatment with Exjade. 
Pretrage funkcija bubrega i jetre treba provoditi prije početka liječenja i u redovitim vremenskim razmacima tijekom uzimanja lijeka Exjade.
What benefits of Exjade have been shown in studies? 
Koje su koristi od lijeka Exjade utvrđene u ispitivanjima?
Exjade contains the active substance deferasirox. 
Lijek Exjade sadržava djelatnu tvar deferasiroks.
• patients from 6 years of age who have beta thalassaemia major (an inherited blood disorder in which patients do not have enough normal haemoglobin in the blood) and who receive frequent blood transfusions; 
• bolesnika u dobi od 6 godina i starijih koji imaju beta-talasemiju major (nasljedni poremećaj krvi pri kojem bolesnici nemaju normalne vrijednosti hemoglobina u krvi) i koji često primaju transfuziju krvi;
It is available as film-coated tablets, dispersible tablets and granules. 
Lijek je dostupan u obliku tableta obloženih filmom, tableta za oralnu suspenziju te u obliku granula.
Interruption of treatment with Exjade should be considered in patients who develop this condition. 
U bolesnika kod kojih je nastalo to stanje trebalo bi razmotriti prekid liječenja lijekom Exjade.
Cases of kidney and liver failure have been reported with Exjade. 
Pri uporabi lijeka Exjade zabilježeni su slučajevi zatajenja bubrega i jetre.
For the full list of side effects of Exjade, see the package leaflet. 
Potpuni popis nuspojava zabilježenih pri primjeni lijeka Exjade potražite u uputi o lijeku.